Integrated care for alcohol use and alcohol-related liver disease
Integrated therapies for alcohol use and ALD (ITAALD) Network - IU Clinical Center
Combining addiction treatments, counseling, and liver-focused therapies for people with alcohol-related liver disease—especially severe alcohol-associated hepatitis—to help reduce drinking and improve survival.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11194526 on NIH RePORTER |
What this research studies
As a patient you would get coordinated care from addiction specialists and liver doctors working together. The network runs clinical trials and programs that may include medicines for alcohol use disorder (for example acamprosate), novel liver-directed drugs such as IL-22, and behavioral therapy like motivational interviewing. Some work focuses on people hospitalized with severe alcohol-associated hepatitis to try to reduce short-term deaths and prevent relapse to drinking. Care is delivered at participating clinical centers with close monitoring and follow-up.
Who could benefit from this research
Good fit: Adults with alcohol-associated liver disease, including those with severe alcohol-associated hepatitis or ongoing harmful alcohol use who can attend a participating clinical center, are the intended candidates.
Not a fit: People without alcohol-related liver disease, those not willing to engage in addiction treatment, or patients already needing urgent transplant-level care may not benefit from these interventions.
Why it matters
Potential benefit: If successful, this integrated approach could reduce deaths and hospitalizations and help people with alcohol-related liver disease stop drinking and stay healthier.
How similar studies have performed: Previous trials have had mixed results—some steroid studies in severe alcohol-associated hepatitis showed unexpected survival signals and acamprosate is thought to be relatively safe in liver disease, but IL-22 and fully integrated AUD/ALD care approaches remain relatively new and need confirmation.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Chalasani, Naga P — Indiana University Indianapolis
- Study coordinator: Chalasani, Naga P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.